Verrica Pharmaceuticals Inc (NASDAQ:VRCA)
| 8.20 Delayed Data As of Sep 25 |  +0.37 / +4.73%Today’s Change | 6.02 Today|||52-Week Range 18.67 | -48.40% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Pharmaceuticals: Major | MARKET CAP $210.4M |
Company Description
Verrica Pharmaceuticals, Inc. operates as a clinical-stage medical dermatology company, which engages in identifying, developing, and commercializing pharmaceutical products for the treatment of skin diseases. Its lead product VP-102, is a proprietary topical therapy used in common skin indications including Molluscum contagiosum and Verruca Vulgaris. The company was founded by Matthew Davidson on July 3, 2013 and is headquartered in West Chester, PA.
Contact Information
Verrica Pharmaceuticals, Inc. 10 North High Street West Chester Pennsylvania 19380 |
Employees
Shareholders
| Mutual fund holders | 9.64% |
| Individual stakeholders | 59.50% |
| Other institutional | 23.23% |
Top Executives
| Ted White | President, Chief Executive Officer & Director |
| A. Brian Davis | Chief Financial Officer |
| Gary Goldenberg | Chief Medical Officer |
| Eugene Scavola | Executive Vice President-Technical Operations |
| Joe Bonaccorso | Chief Commercial Officer |
